SCA
ESPR

Secor Capital Advisors’s Esperion Therapeutics ESPR Stock Holding History

Secor Capital Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-28,514
Closed -$1.12M – 461
2018
Q2 		$1.12M Buy
28,514
+10,015
+54% +$506K 0.1% 288
2018
Q1 		$1.34M Buy
+18,499
New +$1.36M 0.11% 256
2016
Q2 		– Sell
-11,543
Closed -$195K – 615
2016
Q1 		$195K Buy
+11,543
New +$186K 0.03% 548

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Secor Capital Advisors's ESPR Position: Q3 2018 in Review

Secor Capital Advisors sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 28,514 shares — an estimated $1.12M sold.

Secor Capital Advisors first reported a position in ESPR in Q1 2016 and held it in 3 quarters. The position peaked at $1.34M in Q1 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Secor Capital Advisors reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 28,514 Esperion Therapeutics shares in Q3 2018, an estimated $1.12M.
  • Secor Capital Advisors first reported a position in Esperion Therapeutics in Q1 2016 and held it in 3 quarters.
  • Secor Capital Advisors's Esperion Therapeutics position peaked at $1.34M in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.